Click here to view online. Add this email to your safelist.

AstraZeneca logo

Datopotamab deruxtecan-based combinations show promising clinical activity in patients with advanced non-small cell lung cancer

9 August 2022

Initial results from the TROPION-Lung02 Phase Ib trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in patients with previously untreated or pretreated, advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. Results were presented during a late-breaking presentation (#MA13.07) today at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (WCLC).

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2022

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.